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NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLERO-
SIS
Burt, R.K.1, Oyama, Y.1, Statkute, L.1, Quigley, K.1, Weppner, C.1,
Krosnjar, N.1, Verda, L.1 Division of Immunotherpay, Department of
Medicine, Northwestern University Feinberg School of Medicine, Chi-
cago, IL.
We have previously reported that autologous hematopoietic stem
cell transplantation (HSCT) using a cancer-speciﬁc myeloablative
regimen (cyclophosphamide [CY] and total body irradiation) failed
to improve the neurologic disability (EDSS) score or even forestall
progressive neurologic decline in patients with secondary progres-
sive (axonal degenerative) multiple sclerosis. We, therefore, rede-
signed our approach to employ a non-myeloablative lymphoabla-
tive conditioning regimen composed of agents speciﬁcally used to
treat multiple sclerosis (CY and CAMPATH-1H). Patients with
relapsing-remitting (inﬂammatory) multiple sclerosis with pre-
transplant EDSS of 2.0 to 6.0 were candidates for our study.
Nineteen patients were treated. Peripheral blood stem cells were
mobilized with intravenous (IV) CY 2g/m2 and subcutaneous G-
CSF 10 mcg/kg/day. Conditioning regimen consisted of IV CY
200 mg/kg and CAMPATH-1H 20 mg. Mobilization and condi-
tioning regimens were well tolerated. No patient had either an
early or late infection, only half of the patients had a neutropenic
fever. Of those who developed fever during the transplant, fever
lasted less than 24 hours and was related to CAMPATH-1H or
stem cell infusion. One-half of the patients never required RBC
transfusion and one quarter never required a platelet transfusion.
The mean day of white blood cell engraftment was day 8. The
mean day of hospital discharge was day 10. CD4 recovery oc-
curred by 6 months. The EDSS neurologic rating scale that varies
from 0 (normal) to 10 (dead from neurologic disease) is evaluated
after HSCT every 6 months twice then annually. In 15 patients
who were followed for 6 or more months, the EDSS has improved
by at least one point in the majority (8 patients), remained un-
changed in 6 and deteriorated in only 1. A randomized trial, the
Multiple Sclerosis International Stem Cell Transplant (MIST) trial
comparing autologous non-myeloablative HSCT to continued
standard therapy for patients with refractory relapsing-remitting
MS is currently registering patients. Reference: Burt RK, Cohen
BA, Russell E, Spero K, Joshi, A Oyama, Y, Karpus WJ, Luo K,
Jovanovic, J, Traynor AE, Burns, WH. Hematopoietic stem cell
transplantation for progressive multiple sclerosis: failure of intense
immune suppression to prevent disease progression in patients
with high disability scores. Blood, 102(7):2373-8, 2003.
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AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
REFRACTORY CROHN’S DISEASE, THE SUMMARY OF PHASE I TRIAL
Oyama, Y.1, Craig, R.M.1, Quigley, K.1, Statkute, L.1, Burt, R.K.1
Division of Immunotherapy, Department of Medicine, Northwestern
University Feinberg School of Meidicine, Chicago, IL.
Background: Crohn’s disease (CD) is an immunologically me-
diated inﬂammatory disease of the gastrointestinal tract. In theory,
immune ablation followed by autologous hematopoietic stem cell
transplantation (HSCT) can induce disease remission by destroy-
ing old and reconstituting a new immune system. Methods: We
conducted a phase I autologous non-myeloablative immunoabla-
tive HSCT trial in 17 patients with severe refractory CD. Patients
were less than 60 years old with a Crohn’s Disease Activity Index
(CDAI) of 250–400 or Craig Crohn’s Severity Index (CCSI) of
17 despite conventional therapy including inﬂiximab. Peripheral
blood stem cells were mobilized with intravenous (IV) cyclophos-
phamide (CY) 2g/m2 and subcutaneous G-CSF 10 mcg/kg/day.
The immunoablative conditioning regimen consisted of 200 mg/kg
IV CY, and 90 mg/kg IV equine antithymocyte globulin. The graft
was CD34 enriched. Results: There was no treatment related
mortality. The procedure was well tolerated. Anticipated neutro-
penic fever, nausea, vomiting, diarrhea, and anorexia were common
and responded well to medical therapy. The median days for
neutrophil and platelet engraftment were 9 (range 7–11) and 9
(range 8–18, three patients never below 20 K/ul), respectively. The
median infused CD34 and CD3 cell counts were 4.83 106/kg
(range 1.73–24.88  106/kg) and 0.56  104/kg (range 0.0–3.09 
104/kg), respectively. Pre-transplant median CDAI and CCSI were
282 (range 101–358) and 24 (range 18–33). After the transplant,
symptoms and CDAI/CCSI tended to improve quickly and dra-
matically, and radiographic and colonoscopy ﬁndings have been
improving gradually over months to years following HSCT. For
patients with 	6 months follow up, 12 out of 15 patients entered
sustained disease remission deﬁned by a CDAI 150 or reduction
of a CCSI 10 after median follow-up of 29 (range 11–48)
months. Conclusions: Autologous HSCT has a marked durable
salutary effect on CD activity and is a safe intervention for patients
with refractory Crohn’s disease. A randomized study (KISS trial:
C[K]rohn’s Immune Suppression vs Stem Cell Transplant) com-
paring autologous immunoablative HSCT to standard therapy is
now enrolling patients.
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AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR DIFFUSE SCLERODERMA
Oyama, Y.1, Statkute, L.1, Barr, W.G.1, Krosnjar, N.1, Yaung, K.1,
Weppner, C.1, Burt, R.K.1 Div. of Immunotherapy, Dept. of Medicine,
Northwestern University Feinberg School of Medicine, Chicago, IL.
Patients with diffuse cutaneous scleroderma with visceral in-
volvement have an overall 10-year survival of 35–68%. There is no
known therapy that is able to alter the natural course of the disease.
Here we report outcomes of autologous HSCT phase I study
utilizing non-myeloablative lymphoablative conditioning regimen.
Nine patients with diffuse scleroderma and poor clinical features
were enrolled. Candidates were less than 65 years old and had
either Rodnan skin score of more than 14 or lung diffusion capacity
of carbon monoxide (DLCO) less than 80%, interstitial lung dis-
ease, elevated ESR, renal involvement, or abnormal electrocardio-
gram. Patients with pulmonary hypertension (pulmonary artery
systolic pressure 	45 mmHg) were excluded. Peripheral blood
stem cells were mobilized with intravenous (IV) cyclophosphamide
(CY) 2g/m2 and subcutaneous granulocyte colony-stimulating fac-
tor 10 mcg/kg daily. The graft was not manipulated. The condi-
tioning regimen consisted of CY 200 mg/kg and rabbit antithymo-
cyte globulin (rATG) 7.5 mg/kg. The procedure was well
tolerated. Anticipated cytopenias, neutropenic fever, and mild ﬂuid
overload were easily controlled. White blood cells and platelets
both engrafted on average day 8 (range days 7–9 and days 0–10,
respectively). The median numbers of infused CD34 and CD3
cells were 8.31  106/kg (range 2.35–14.7  106/kg) and 2.03 
108/kg (range 0.41–6.83  108/kg), respectively. We observed a
marked improvement of skin score in all subjects, whereas cardiac
function (ejection fraction, pulmonary artery systolic pressure),
pulmonary function (DLCO) and renal function (creatinine) re-
mained stable. One patient with advanced disease and poor per-
formance status died 2 years after the transplant from progressive
disease. Two patients developed recurrence of skin tightness with-
out compromising organ function, however, with institution of
mycophenolate mofetil both showed gradual improvement of skin
scores. After median follow-up of 20 (range 5–32) months, the
overall survival is 89% (8 out of 9 patients) and progression-free
survival with continuing improvement is 67% (6 out of 9 patients).
Autologous HSCT with CY/rATG conditioning regimen is safe
and effective. A randomized study (ASSIST: American Sclero-
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